20:53 , Mar 20, 2019 |  BC Innovations  |  Translation in Brief

Sangamo’s ZFN linkers finger new options

Sangamo is using new linkers to expand the structural variety of the ZFNs it designs and increase the odds of finding ZFNs with high editing efficiency and specificity for their targets. Conventional zinc finger nucleases...
22:40 , Mar 18, 2019 |  BC Extra  |  Financial News

OrbiMed, Arix lead Imara's $63M B round

Imara will use its $63 million series B round to prepare lead compound IMR-687 for a Phase III program in adults with sickle cell disease, and to position the oral phosphodiesterase-9 (PDE-9) inhibitor for pediatric...
17:44 , Mar 15, 2019 |  BC Week In Review  |  Clinical News

Mitsubishi Tanabe planning Japanese submission for vadadustat

Akebia said partner Mitsubishi Tanabe plans to submit a regulatory application in Japan this year for vadadustat to treat anemia due to chronic kidney disease (CKD) after reporting that the product met the primary endpoints...
17:34 , Mar 15, 2019 |  BC Week In Review  |  Clinical News

Shield's oral Feraccru non-inferior to IV Injectafer in Phase IIIb

Shield said oral Feraccru ferric maltol met the primary endpoint of non-inferiority to IV Injectafer ferric carboxymaltose in the Phase IIIb AEGIS-H2H trial to treat iron deficiency anemia in adults with inflammatory bowel disease (IBD)....
20:42 , Mar 1, 2019 |  BC Week In Review  |  Clinical News

CRISPR, Vertex dose first β-thalassemia patient, begin enrolling sickle cell patients in Phase I trials of CRISPR therapy

CRISPR Therapeutics AG (NASDAQ:CRSP) and Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) dosed the first patient in a Canadian and European Phase I/II trial of CTX001 to treat transfusion-dependent β-thalassemia, and enrolled the first patient in a U.S....
18:12 , Feb 15, 2019 |  BC Week In Review  |  Financial News

EdiGene raises around $10M in pre-B+ round

Gene editing company EdiGene Inc. (Beijing, China) closed a pre-B+ round of financing to raise about RMB70 million ($10.3 million). In August, EdiGene raised about $15 million in a pre-B round (see "Lilly Asia Ventures...
03:40 , Jan 18, 2019 |  BC Innovations  |  Product R&D

Modality moves at Vertex

In licensing a suite of newly discovered gene editing tools, Vertex Pharmaceuticals Inc. is broadening its options for solving problems that its core small molecule technology can’t address. On Jan. 3, Vertex announced a deal...
02:20 , Jan 18, 2019 |  BC Innovations  |  Targets & Mechanisms

Exploring 3-D genomic white space

Gene regulation is offering a new class of targets that operate on a higher level than DNA sequences and epigenetic markers: 3-D genomic structures. While strategies to drug the 3-D genome are still in their...
18:03 , Jan 11, 2019 |  BC Week In Review  |  Clinical News

Following China approval, FibroGen's anemia drug meets in five additional Phase III trials

FibroGen Inc. (NASDAQ:FGEN) and AstraZeneca plc (LSE:AZN; NYSE:AZN) reiterated plans to submit an NDA to FDA this half for roxadustat to treat anemia in patients with chronic kidney disease (CKD) after the compound met the...
19:26 , Dec 21, 2018 |  BC Week In Review  |  Clinical News

Achillion discontinuing PNH monotherapy

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) said it will discontinue development of ACH-4471 as oral monotherapy treatment of paroxysmal nocturnal hemoglobinuria in favor of an earlier stage compound. The decision is a delay for Achillion as it...